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Changes of Serum Fibroblast Growth Factor 21 Level in Acute Myocardial
Infarction Patients
Wenduo Zhang1
1Beijing Hospital, China
BACKGROUND High levels of FGF-21 are founded in CHD patients.
OBJECTIVE However, the changes of plasma levels of FGF-21 in acute
myocardial infarction patients in unknown. To explore characteristics
of FGF-21 in patients with AMI, we measured the serum concentra-
tions of FGF-21 in 100 Chinese subjects (include 45non-AMI and
55AMI) and analyzed its association with a cluster of metabolic pa-
rameters and clinical end points.
METHODS 55 patients with acute myocardial infarction and 45 pa-
tients without acute myocardial infarction were enrolled. Serum
fasting blood glucose, BNP, CK, CK-MB and TNT total cholesterol,
HDL-c, LDL-c, and triglycerides were measured in all patients, Serum
FGF21 of the 1st day, 3rd day, 7th day from the onset of syndrome
were determined. All AMI patients was followed by 30days.
RESULTS The subjects with AMI (n ¼ 55) showed signiﬁcantly higher
serum FGF21 than those without AMI (0.14 (0.11-0.20) vs. 0.25 (0.16-
0.34), P < 0.001), Their FGF21 levels peaked approximately in 24 h
after the onset of AMI and remained high for 7 days. FGF21 were
identiﬁed as an independent factors associated with AMI (odds ratio ¼
1.432, 95% conﬁdence interval: 1.06-1.951., P ¼ 0.003).CONCLUSION High levels of FGF-21 are signiﬁcantly higher in AMI
patients and associated with adverse events. The paradoxical increase
of serum FGF-21 in CHD patients may indicate a compensatory
response or resistance to FGF-21.TCTAP A-006
Clinical Signiﬁcance of ST-Segment Changes in Lead aVR for Patients with
Acute Coronary Syndrome
Zhen Guo Ji1
1The Third Hospital of Shijiazhuang City, China
BACKGROUND Acute occlusion or critical stenosis in the coronary
artery leads to acute coronary syndrome (ACS). Many studies have
shown that ST-segment depression on the admission electrocardio-
gram (ECG) is a strong predictor of poor outcomes in patients with
ACS. ECG changes in the aVR lead may play an important role in the
prognosis of patients with ACS. The aim of our study was to analyze
the prognostic value of the ST-segment changes in aVR in the initial
standard 12-lead ECG performed on admission.
METHODS 446 ACS patients were enrolled and divided into three
groups according to ST-segment changes in aVR: group 1 (ST-segment
no change), group 2 (ST-segment elevation) and group 3 ( ST-segment
depression). The clinical data and global registry of acute coronary
events (GRACE) risk score were compared among three groups.
RESULTS (1) The differences were statistically signiﬁcant among
three groups in the number of previous myocardial infarction, three-
coronary artery lesion and left main lesion (table 1, p<0.05). The in-
cidences were signiﬁcantly higher in ST-segment elevation group than
those in other two groups. (2) GRACE risk scores: The differences were
statistically signiﬁcant among three groups (p<0.05) and further
comparison as follow. Hospital mortality risk score: The scores were
signiﬁcantly higher in ST-segment elevation group than those in ST-
segment no change group (p<0.05). Hospital myocardial infarction
risk score: The scores were signiﬁcantly higher in both ST-segment
elevation and ST-segment depression groups than those no change in
ST-segment group (p<0.05). Mortality risk score of outside hospital
after 6 months: The scores were signiﬁcantly higher in ST-segment
elevation group than both in depression and no change in ST-segment
of aVR groups (p<0.05). Myocardial infarction risk score of outside
hospital after 6 months: The scores were signiﬁcantly higher in ST-
segment elevation than those in ST-segment depression group
(p<0.05).
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lead aVR in patients with ACS. More adverse events existed in ST-
segment elevation of aVR. The prognosis in other groups has better
clinical results.
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Routine Follow-up Coronary Angiography Versus Clinical Follow-up Only
in Acute ST-Segment Elevation Myocardial Infarction Patients Undergoing
Primary Percutaneous Coronary Intervention with Drug-Eluting Stents:
3-Year Clinical Follow-up Results
Seung-Woon Rha,1 Byoung Geol Choi,1 Se Yeon Choi,1 Shaopeng Xu,2
Jabar Ali,3 Harris Ngow,4 Ji Bak Kim,1 Cheol Ung Choi,1 Eung Ju Kim,1
Dong Joo Oh1
1Korea University Guro Hospital, Korea (Republic of); 2Tianjin General
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BACKGROUND It is unclear whether the routine follow up (FU) cor-
onary angiography (CAG) regardless of patient’s symptoms after
successful primary percutaneous coronary intervention (PCI) with
drug-eluting stents (DESs) in acute ST elevation myocardial infarction
(STEMI) patients (pts) is beneﬁcial or not.
METHODS The study population consisted of 447 consecutive STEMI
patients (pts) underwent PCI with unrestricted utilization of DESs
from January 2004 to May 2011. Routine FU CAG was performed be-
tween 6 to 9 months following index PCI and was decided by indi-
vidual physician’s discretion. Rests of the pts were clinically followed
and ischemic driven events were captured. Clinical events including
mortality, myocardial infarction (MI) and clinically driven PCI before 9
months were excluded in both groups. Cumulative clinical outcomes
up to 3 years were compared between the Routine CAG group (n ¼ 244
pts) and Clinical FU group (n ¼ 203 pts). To adjust potential con-
founders, a propensity score matched (PSM) analysis was performed
using the logistic regression model.
RESULTS After PSM analysis, 2 propensity-matched groups (129 pairs,
n ¼ 258 pts, C-statistic ¼ 0.762) were generated and the baseline
characteristics of the two groups were balanced. At 3 years, the inci-
dence of individual hard endpoints including mortality, MI, major
adverse cardiac events (MACEs) were similar between the two groups
excepted that Routine CAG group had higher incidence of any revas-
cularization, particularly non-target vessel revascularization (NTVR)
than the control group (Table).
CONCLUSION Despite the expected beneﬁcial effects, routine FU CAG
following index primary PCI with DESs in STEMI pts was associated
with higher incidence of repeat PCI including NTVR up to 3-year
clinical follow-up.TCTAP A-008
Comparison of Sirolimus-, Everolimus-, Biodegradable Polymer Stent, and
Endothelial Progenitor Cell Capture Stent in Patients with ST-Elevation
Myocardial Infarction
Seung-Jung Park,1 Hyun Woo Park,1 Se Hun Kang,1 Min Su Kim,1
Hee-soon Park,1 Byeong Joo Bae,1 Sang Soo Cheon,1 Jae Hyung Roh,1
Pil Hyung Lee,1 Mineok Chang,1 Sung Han Yoon,1 Jung-Min Ahn,1
Duk-Woo Park,1 Soo-Jin Kang,1 Seung-Whan Lee,1 Young-Hak Kim,1
Cheol Whan Lee,1 Seong-Wook Park1
1Asan Medical Center, Korea (Republic of)
BACKGROUND We compared the efﬁcacy and safety of sirolimus-
eluting stents with Parylene C (SESs), everolimus-eluting stents with
poly n-butyl methacrylate (EESs), biodegradable stent (BP-DESs), and
endothelial progenitor cell capture stents (EPCCSs).
METHODS From the IRIS-DES registry, we identiﬁed 1517 patients
treated using PCI with SESs (N ¼ 372), EESs (N ¼ 405), BP-DESs (N ¼
300), and EPCCSs (N ¼ 440) in ST-elevation myocardial infarction
(STEMI). Major adverse cardiac events (MACE) were deﬁned using
composite of death, myocardial infarction, and target vessel revas-
cularization at 24 months.
RESULTS The average number of stent used was 1.6  0.8. At 2 years,
there was no difference in the incidence of MACE (8.5% in SESs, 9.9%
in EES, 10.2% in BP-DES, and 12.8% in EPCCS, P ¼ 0.281), death (5.0%
in SESs, 4.3% in EES, 4.4%in BP-DES, and 6.2% in EPCCS, P ¼ 0.718),
MI (0.6% in SESs, 1.6% in EES, 1.5%in BP-DES, and 1.5% in EPCCS, P ¼
0.572), and TVR (3.8% in SESs, 5.9% in EES, 4.8% in BP-DES, and 6.5%
in EPCCS, P ¼ 0.313). The EPCCSs group showed trend of higher rate in
any revascularization, but no signiﬁcantly statistical difference (6.6%
in SESs, 9.1% in EES, 7.2% in BP-DES, and 11.6% in EPCCS, P ¼ 0.313).
The cumulative rates of Academic Research Consortium deﬁned def-
inite stent thrombosis were 0.3% in SESs, 1.2% in EESs, 0.7% in BP-
DESs, and 1.6% in EPCCSs (P ¼ 0.239).
CONCLUSION The 4 different DESs showed no signiﬁcant difference
in clinical outcome at 2-year follow-up in patients with STEMI.
